Perioperative Topical Nepafenac Enhances Early Anatomical and Functional Recovery After Epiretinal Membrane Surgery: A Prospective Comparative Study
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change in Best-Corrected Visual Acuity (BCVA)
研究概览
简要总结
This prospective comparative study evaluates whether perioperative topical nepafenac improves early anatomical and functional recovery after pars plana vitrectomy with epiretinal membrane and internal limiting membrane peeling. The study compares postoperative visual acuity, central macular thickness, and other clinical outcomes between patients treated with perioperative nepafenac and those receiving standard postoperative care.
详细描述
Epiretinal membrane (ERM) surgery generally results in favorable anatomical outcomes; however, postoperative retinal inflammation may delay visual and structural recovery. Nepafenac is a topical nonsteroidal anti-inflammatory drug with excellent intraocular penetration and may reduce postoperative inflammation.
This prospective comparative study investigates the effect of perioperative topical nepafenac on early postoperative recovery following pars plana vitrectomy with epiretinal membrane and internal limiting membrane peeling.
Participants were assigned to receive either perioperative topical nepafenac or standard postoperative treatment. The primary objective is to compare anatomical recovery, measured by optical coherence tomography, and functional recovery, assessed by best-corrected visual acuity. Secondary outcomes include changes in central macular thickness and postoperative complications.
The findings may help determine whether perioperative topical nepafenac provides additional benefit in improving early postoperative outcomes after epiretinal membrane surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 18 years or older.
- •Diagnosis of idiopathic epiretinal membrane requiring pars plana vitrectomy.
- •Best-corrected visual acuity impairment and/or metamorphopsia attributed to epiretinal membrane.
- •Ability to provide written informed consent.
- •Willingness to complete the scheduled follow-up examinations for 6 months.
排除标准
- •- Previous vitreoretinal surgery in the study eye.
- •Other retinal diseases that could affect visual or anatomical outcomes (e.g., diabetic retinopathy, retinal vein occlusion, age-related macular degeneration).
- •Significant ocular trauma.
- •Active ocular inflammation or infection.
- •Advanced glaucoma or optic neuropathy affecting visual function.
- •Media opacity preventing adequate retinal imaging.
结局指标
主要结局
Change in Best-Corrected Visual Acuity (BCVA)
时间窗: 6 months after surgery
To compare the change in best-corrected visual acuity (logMAR) between the perioperative nepafenac group and the control group following epiretinal membrane surgery.
次要结局
- Change in Central Macular Thickness (CMT)(6 months after surgery)
- Integrity of the Ellipsoid Zone(6 months after surgery)
- Postoperative Complications(6 months after surgery)